Paul Volberding

UCSF-GIVI Center for AIDS Research, University of California San Francisco, United States of America

Paul A. Volberding, MD

Academic positions:
- Chief of Medical Service, San Francisco Veterans Affairs Medical Center
- Vice-chair, Department of Medicine, UCSF
- Director, Center for AIDS Research, University of California, San Francisco
- Chief, Medical Oncology Division, San Francisco General Hospital
- Director, AIDS Program, San Francisco General Hospital
- Professor of Medicine, University of California, San Francisco
- Full Member, Cancer Center, University of California, San Francisco

Any industry positions (last five years):
Dr Volberding is on the scientific advisory boards of Pfizer, GSK, Gilead, Schering, and BMS amongst others.

Research interests:
Dr. Volberding's research career began with investigations of HIV related malignancies, especially Karposis Sarcoma. His primary research focus, however, shifted to clinical trials of antiretroviral drugs. He has been instrumental in testing many compounds, but is best known for groundbreaking trials establishing standards of care for the use of zidovudine in asymptomatic HIV infection.

Any other information:
Dr. Volberding has served on numerous key national committees over the course of the AIDS epidemic, including the National Academy of Sciences (Institute of Medicine) AIDS Policy Review Steering Committee, National Institutes of Health (NIH) AIDS Drug Selection Committee, National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Executive Committee, Institute of Medicine Round Table, and the AIDS Clinical Trials Group Executive Committee.

Dr. Volberding has written numerous research and review articles. He is the coeditor-in-chief of the Journal of Acquired Immune Deficiency Syndromes, and is the founder and chair of the board of the International AIDS Society-USA. He is also the coeditor of The Medical Management of AIDS, the most widely used textbook of HIV medicine, now in its sixth edition. In 1999, he was elected to the Institute of Medicine of the National Academy of Sciences.

Any competing interests declared are displayed with individual evaluations.

Section Head: Infectious Diseases > HIV Infection & AIDS: Clinical (since 15 November 2005)

Paul Volberding is a Section Head for HIV Infection & AIDS: Clinical, part of the INFECTIOUS DISEASES Faculty. The role of a Section Head is to work with their Co-Section Head(s) to divide the Section (sub-specialty area) into its component areas of research, nominate leaders in those areas as Faculty Members, and offer ongoing oversight of the content within their Section. They are not asked to evaluate articles, although we do, of course, welcome them.

Links

http://chi.ucsf.edu/chi?page=home-02-02

All recent recommendations

• 6.0
  CD4+ count-guided interruption of antiretroviral treatment.
  Recommended by Paul Volberding
  
• 3.0
  Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
  Recommended by Paul Volberding
  
• 3.0
  The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
  Recommended by Paul Volberding
  
• 4.8
  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.
  Recommended by Anthony Harries, Paul Volberding
  
• 6.4
  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
  Recommended by Paul Volberding, Kiat Ruxrungtham
  
• 3.0
  Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients.
  Recommended by Paul Volberding
  
• 3.0
  Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
  Recommended by Paul Volberding
  
• 6.0
  Narrative review: the promotion of gabapentin: an analysis of internal industry documents.
  Recommended by Paul Volberding
  
• 6.0
  Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
  Recommended by Paul Volberding
  
• 6.4
  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.
  Recommended by Paul Volberding, Pam Sonnenberg
  
• 6.4
  The survival benefits of AIDS treatment in the United States.
  Recommended by Anthony Harries, Paul Volberding
  
• 3.0
  Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.
  Recommended by Paul Volberding
  
• 3.0
  Elevated incidence of lung cancer among HIV-infected individuals.
  Recommended by Paul Volberding